<DOC>
	<DOCNO>NCT00002619</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bone marrow peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow autologous bone marrow peripheral stem cell transplantation treat patient glioblastoma multiforme brain stem tumor .</brief_summary>
	<brief_title>Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Glioblastoma Multiforme Brain Stem Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate overall survival , progression-free interval , time progression recurrence patient nondisseminated glioblastoma multiforme diffuse intrinsic brain stem tumor nonprogressive follow surgery ( feasible ) involved-field irradiation treat intensive chemotherapy follow autologous peripheral blood stem cell ( PBSC ) autologous bone marrow ( ABM ) rescue . II . Estimate toxicity myeloablative chemotherapy thiotepa ( TSPA ) follow carboplatin ( CBDCA ) patient . III . Evaluate pharmacokinetic interaction high-dose CBDCA , TSPA , triethylenephosphoramide ( metabolite TSPA ) impact subsequent toxicity . IV . Evaluate effectiveness autologous stem cell restore hematopoiesis follow myeloablative therapy . OUTLINE : All patient undergo bone marrow stem cell harvest ( investigator option ) later 12 week completion radiotherapy . The following acronym use : ABM Autologous Bone Marrow CBDCA Carboplatin , NSC-241240 G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 PBSC Peripheral Blood Stem Cells TSPA Thiotepa , NSC-6396 2-Drug Myeloablative Chemotherapy follow Hematopoietic Rescue . TSPA ; CBDCA ; follow ABM PBSC ; G-CSF . PROJECTED ACCRUAL : 60 patient enter 3 year . If 5 patient arm experience treatment-related mortality , accrual discontinue .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Glioblastoma multiforme ( GBM ) brain stem tumor follow surgery ( feasible ) local radiotherapy , follow : Pathologically confirm primary GBM Gliosarcomas multifocal GBM eligible Unbiopsied diffuse intrinsic pontine tumor Nonenhancing gadolinium MRI T1 hypodense T2 hyperdense No recurrent progress disease follow radiotherapy No leptomeningeal dissemination radiographic evaluation include head MRI either wholespine MRI gadolinium myelogram Positive CSF cytology alone allow No extraneural metastasis PATIENT CHARACTERISTICS : Age : 6 60 Performance status : Karnofsky 70 % 100 % ( age 16 ) Lansky 70 % 100 % ( age 616 ) Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL AST ALT less 5 time normal PT aPTT normal ( consult principal investigator abnormal ) Renal : Creatinine clearance least 50 mL/min/1.73 sqm Cardiovascular : No evidence myocardial infarction ischemia EKG Other : No active infection time leukapheresis Able tolerate anticoagulation PRIOR CONCURRENT THERAPY : Radical surgery involvedfield radiotherapy ( least 4,500 cGy ) complete within 6 week prior entry Second surgical debulking follow radiotherapy strongly encourage patient residual tumor mass suspect radionecrosis Requirement surgery waive unresectable brainstem tumor No prior chemotherapy except corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>